Daewoong Co., Ltd. (003090.KS)
KRW 19580.0
(-1.11%)
KRW 19580.0
(-1.11%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 922.47 Billion KRW | 4.9% |
| 2022 | 879.4 Billion KRW | 13.23% |
| 2021 | 776.67 Billion KRW | 7.78% |
| 2020 | 720.61 Billion KRW | 12.26% |
| 2019 | 641.92 Billion KRW | 2.24% |
| 2018 | 627.85 Billion KRW | 2.95% |
| 2017 | 609.84 Billion KRW | 1.19% |
| 2016 | 602.65 Billion KRW | 45.63% |
| 2015 | 413.82 Billion KRW | 37.03% |
| 2014 | 302 Billion KRW | 42.86% |
| 2013 | 211.4 Billion KRW | 79.42% |
| 2012 | 117.82 Billion KRW | -16.35% |
| 2011 | 140.85 Billion KRW | -50.65% |
| 2010 | 285.42 Billion KRW | 3.02% |
| 2009 | 277.05 Billion KRW | 2.14% |
| 2008 | 271.25 Billion KRW | 53.71% |
| 2007 | 176.47 Billion KRW | 11.49% |
| 2006 | 158.29 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 971.6 Billion KRW | 5.33% |
| 2024 Q2 | 1078.19 Billion KRW | 10.97% |
| 2023 Q3 | 892.3 Billion KRW | 2.72% |
| 2023 FY | 922.47 Billion KRW | 4.9% |
| 2023 Q1 | 877.88 Billion KRW | -0.17% |
| 2023 Q2 | 868.65 Billion KRW | -1.05% |
| 2023 Q4 | 922.47 Billion KRW | 3.38% |
| 2022 Q4 | 879.4 Billion KRW | 6.39% |
| 2022 Q1 | 797.32 Billion KRW | 2.66% |
| 2022 Q2 | 809.12 Billion KRW | 1.48% |
| 2022 FY | 879.4 Billion KRW | 13.23% |
| 2022 Q3 | 826.58 Billion KRW | 2.16% |
| 2021 Q2 | 767.32 Billion KRW | -1.95% |
| 2021 Q1 | 782.58 Billion KRW | 8.6% |
| 2021 Q3 | 779.79 Billion KRW | 1.63% |
| 2021 Q4 | 776.67 Billion KRW | -0.4% |
| 2021 FY | 776.67 Billion KRW | 7.78% |
| 2020 Q3 | 695.65 Billion KRW | 11.18% |
| 2020 FY | 720.61 Billion KRW | 12.26% |
| 2020 Q2 | 625.73 Billion KRW | -3.71% |
| 2020 Q1 | 649.86 Billion KRW | 1.24% |
| 2020 Q4 | 720.61 Billion KRW | 3.59% |
| 2019 Q1 | 656.57 Billion KRW | 4.57% |
| 2019 Q2 | 664.35 Billion KRW | 1.18% |
| 2019 Q4 | 641.92 Billion KRW | -3.2% |
| 2019 Q3 | 663.17 Billion KRW | -0.18% |
| 2019 FY | 641.92 Billion KRW | 2.24% |
| 2018 FY | 627.85 Billion KRW | 2.95% |
| 2018 Q4 | 627.85 Billion KRW | 1.88% |
| 2018 Q3 | 616.26 Billion KRW | 0.54% |
| 2018 Q2 | 612.94 Billion KRW | -1.84% |
| 2018 Q1 | 624.41 Billion KRW | 2.39% |
| 2017 FY | 609.84 Billion KRW | 1.19% |
| 2017 Q2 | 597.82 Billion KRW | -1.02% |
| 2017 Q3 | 606.76 Billion KRW | 1.5% |
| 2017 Q4 | 609.84 Billion KRW | 0.51% |
| 2017 Q1 | 604.01 Billion KRW | 0.23% |
| 2016 Q2 | 552.54 Billion KRW | 30.38% |
| 2016 Q4 | 602.65 Billion KRW | 9.51% |
| 2016 Q3 | 550.34 Billion KRW | -0.4% |
| 2016 FY | 602.65 Billion KRW | 45.63% |
| 2016 Q1 | 423.81 Billion KRW | 2.41% |
| 2015 Q4 | 413.82 Billion KRW | -7.85% |
| 2015 FY | 413.82 Billion KRW | 37.03% |
| 2015 Q1 | 322.67 Billion KRW | 6.84% |
| 2015 Q2 | 328.28 Billion KRW | 1.74% |
| 2015 Q3 | 449.08 Billion KRW | 36.8% |
| 2014 Q4 | 302 Billion KRW | 32.18% |
| 2014 Q3 | 228.48 Billion KRW | 12.86% |
| 2014 Q2 | 202.44 Billion KRW | -2.16% |
| 2014 FY | 302 Billion KRW | 42.86% |
| 2014 Q1 | 206.92 Billion KRW | -2.12% |
| 2013 Q1 | 195.38 Billion KRW | 65.83% |
| 2013 Q3 | 171.84 Billion KRW | -3.56% |
| 2013 Q4 | 211.4 Billion KRW | 23.02% |
| 2013 FY | 211.4 Billion KRW | 79.42% |
| 2013 Q2 | 178.18 Billion KRW | -8.8% |
| 2012 Q4 | 117.82 Billion KRW | 0.0% |
| 2012 FY | 117.82 Billion KRW | -16.35% |
| 2012 Q1 | 22.63 Billion KRW | 0.0% |
| 2011 FY | 140.85 Billion KRW | -50.65% |
| 2011 Q1 | 16.5 Billion KRW | 0.0% |
| 2011 Q3 | 14.69 Billion KRW | 12.74% |
| 2011 Q2 | 13.03 Billion KRW | -21.05% |
| 2010 FY | 285.42 Billion KRW | 3.02% |
| 2010 Q2 | 12.49 Billion KRW | 0.0% |
| 2010 Q3 | 12.83 Billion KRW | 2.75% |
| 2009 Q2 | 6.43 Billion KRW | 0.0% |
| 2009 Q3 | 10.13 Billion KRW | 57.46% |
| 2009 Q4 | 13.55 Billion KRW | 33.74% |
| 2009 FY | 277.05 Billion KRW | 2.14% |
| 2008 Q2 | 6.77 Billion KRW | 0.0% |
| 2008 Q4 | 7.33 Billion KRW | -12.57% |
| 2008 Q3 | 8.38 Billion KRW | 23.8% |
| 2008 FY | 271.25 Billion KRW | 53.71% |
| 2007 Q4 | 10.63 Billion KRW | -3.71% |
| 2007 Q2 | 9.03 Billion KRW | 0.0% |
| 2007 FY | 176.47 Billion KRW | 11.49% |
| 2007 Q3 | 11.04 Billion KRW | 22.21% |
| 2006 FY | 158.29 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| PharmGen Science, Inc. | 107.7 Billion KRW | -756.48% |
| Wooridul Huebrain Limited | 17.6 Billion KRW | -5141.261% |